血浆与唾液S100B作为创伤性脑损伤严重程度预测指标的对比分析:基于GCS与MAIS/头部
该多中心前瞻性队列纳入57例成人钝性TBI患者,伤后2–4小时采集血浆与唾液S100B,用ELISA检测,以GCS和MAIS/头部评估TBI严重程度。血浆S100B对GCS和MAIS/头部的AUC分别为0.87和0.83,唾液S100B分别为0.85和0.83。唾液S100B对轻度TBI(MAIS/头部)特异度100%,对中度TBI(MAIS/头部)敏感度100%;血浆S100B对重型TBI(GCS≤8)敏感度100%。两种标志物均不能区分中度与重型损伤,作者认为其可补充现有临床严重程度量表并支持急诊快速决策。
要点
- 伤后2–4小时血浆S100B对GCS区分TBI严重程度的AUC为0.87,对MAIS/头部为0.83。
- 伤后2–4小时唾液S100B对GCS的AUC为0.85,对MAIS/头部为0.83。
- 唾液S100B对轻度TBI(MAIS/头部)特异度100%,对中度TBI(MAIS/头部)敏感度100%。
- 血浆S100B对重型TBI(GCS≤8)敏感度100%。
- 血浆与唾液S100B均不能区分中度与重型TBI。
适用人群与场景
- 成人钝性创伤性脑损伤(TBI)患者,共57例,多中心前瞻性队列纳入。
- 伤后2–4小时采集血浆与唾液样本。
诊断标准与关键阈值
- TBI严重程度分别用格拉斯哥昏迷评分(GCS)和头部简明损伤定级最大值(MAIS/头部)评估。
- 血浆与唾液S100B用ELISA法测定。
研究设计与关键结果
- 多中心前瞻性队列研究,纳入57例成人钝性TBI患者,伤后2–4小时采集血浆与唾液S100B,用ELISA检测。
- 中度和重型TBI患者血浆与唾液S100B浓度均升高。
- 血浆S100B对GCS的AUC=0.87,对MAIS/头部的AUC=0.83。
- 唾液S100B对GCS的AUC=0.85,对MAIS/头部的AUC=0.83。
- 唾液S100B对轻度TBI(MAIS/头部)特异度100%,对中度TBI(MAIS/头部)敏感度100%。
- 血浆S100B对重型TBI(GCS≤8)敏感度100%。
- 血浆与唾液S100B均不能区分中度与重型损伤。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 作者结论:血浆与唾液S100B可有效区分轻度与重型TBI,补充现有临床严重程度量表;唾液采样简单、无创、可行,可能支持急诊快速决策;作者支持将S100B测定整合入TBI管理方案以提高临床准确性和患者结局。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血浆与唾液S100B可补充GCS和MAIS/头部等临床量表,用于区分轻度与重型TBI。
- 作者认为唾液采样简单、无创、可行,可能支持急诊科快速决策。
- 作者支持将S100B测定整合入TBI管理方案以增强临床准确性并改善患者结局。
- 两种标志物均不能区分中度与重型TBI,作者未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Accurate assessment of traumatic brain injury (TBI) severity is essential for clinical management and outcome prediction. Traditional tools, like the Glasgow Coma Scale (GCS) and Maximum Abbreviated Injury Scale for head injuries (MAIS/Head), have limitations, particularly in cases involving sedation, complex injuries, or diffuse brain injuries. This study evaluates the diagnostic accuracy of plasma and salivary S100B levels as biomarkers for TBI severity, based on GCS and MAIS/Head, with emphasis on emergency settings.
METHODS: Multicenter prospective cohort study enrolled 57 adult patients with blunt TBI. TBI severity was assessed using GCS and MAIS/Head. Plasma and salivary S100B samples were collected 2-4h post-injury and measured via ELISA. Receiver operating characteristic (ROC) curves assessed S100B's discriminative capacity for TBI severity.
RESULTS: Plasma and salivary S100B concentrations were higher in moderate and severe TBI cases. ROC analysis revealed strong discriminative performance for plasma (AUC = 0.87 and 0.83) and salivary S100B (AUC = 0.85 and 0.83), for GCS and MAIS/HEAD, respectively. Salivary S100B showed 100 % specificity for mild TBI and 100 % sensitivity for moderate TBI (MAIS/Head). Plasma S100B exhibited 100 % sensitivity for severe TBI (GCS ≤8). Both biomarkers did not distinguish between moderate and severe injuries.
CONCLUSIONS: Plasma and salivary S100B levels effectively discriminate mild from severe TBI, complementing current clinical severity scales. Their use may support rapid decision-making in emergency departments, especially given the simplicity, non-invasiveness, and feasibility of salivary sampling. These findings support integrating S100B measurement into TBI management protocols to enhance clinical accuracy and patient outcomes.
参考来源
- Fernandes LC, de Oliveira Rocha T, Sloboda DA, et al. Comparative analysis of plasma and salivary S100B as predictors of traumatic brain injury severity according to GCS and MAIS/head. Am J Emerg Med. 2025. PMID: 40614699. doi:10.1016/j.ajem.2025.06.058
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。